Skip to main content

Advertisement

Table 3 Multivariate testing: OR (95% CI) to the first quartile of biomarkers investigated vs stroke lesion site (anterior vs posterior) & stroke lesion dimensions

From: Blood biomarkers role in acute ischemic stroke patients: higher is worse or better?

Variable (Units) / Quartiles Site D1 D2 D3 D4
(OR; 95% CI) (OR; 95% CI) (OR; 95% CI) (OR; 95% CI) (OR; 95% CI)
ESR (mm)      
Q1 (< 10) n = 23 1 1 1 1 1
Q2 [10 – 16) n = 30 0.650 (0.212-1.993) 0.473 (0.149-1.501) 2.115 (0.666-6.715) 2.625 (0.478-14.428) 7.981 (0.383-166.240)
Q3 [16 – 30) n = 19 0.758 (0.218-2.632) 0.945 (0.277-3-230) 1.319 (0.380-4.577) 2.800 (0.452-17.318) 6.714 (0.283-159.527)
Q4 [> 30) n = 27 1.040 (0.339-3.190) 0.765 (0.246-2.381) 1.538 (0.488-4.853) 5.250 (1.002-27.514)* 0.855 (0.015-48-430)
Fibrinogen (mg/dL)      
Q1 (< 303) n = 24 1 1 1 1 1
Q2 [303 – 368) n = 25 1.333 (0.415-4.281) 1.366 (0.411-4.539) 0.708 (0.203-2.470) 2.750 (0.479-15.794) 0.958 (0.057-16.243)
Q3 [368 – 462) n = 24 0.824 (0.242-2.797) 1.214 (0.358-4.124) 0.667 (0.190-2.338) 5.500 (1.027-29.451)* 2.091 (0.177-24.734)
Q4 [> 462) n = 25 2.167 (0.682-6.883) 1.619 (0.493-5.319) 0.500 (0.147-1.697) 4.278 (0.789-23.193) 2.000 (0.169-23.623)
Platelets (value x 10.e3/uL)      
Q1 (< 189) n = 25 1 1 1 1 1
Q2 [189 – 256) n = 25 0.434 (0.138-1.371) 0.826 (0.246-2.776) 1.000 (0.291-3.437) 1.000 (0.278-3.598) 13.683 (0.674-277.964)
Q3 [256 – 323) n = 25 0.519 (0.167-1.611) 1.417 (0.444-4.521) 0.583 (0.178-1.906) 0.059 (0.003-1.175)* 3.122 (0.114-85.732)
Q4 [> 323) n = 25 1.000 (0.330-3.033) 1.962 (0.621-6.193) 0.495 (0.153-1.606) 2.032 (0.608-6.797) 1.000 (0.018-56.631)
Blood Albumin (g/dL)      
Q1 (< 2.9) n = 25 1 1 1 1 1
Q2 [2.9 – 3.4) n = 24 1.504 (0.488-4.639) 3.150 (0.815-12.168) 0.227 (0.053-0.981)* 1.059 (0.306-3.658) 5.677 (0.243-132.298)
Q3 [3.4 – 3.8) n = 22 1.273 (0.403-4-19) 5.250 (1.351-20.396)* 0.164 (0.038-0.711)* 0.406 (0.091-1.817) 3.558 (0.129-98.252)
Q4 [> 3.8) n = 25 0.402 (0.102-1.349) 3.500 (0.921-13-307) 0.205 (0.048-0.870)* 0.643 (0.173-2.388) 7.933 (0.366-172.044)
Triglycerides (mg/dL)      
Q1 (< 78) n = 25 1 1 1 1 1
Q2 [78 – 111) n = 26 2.844 (0.913-8.861) 1.474 (0.398-5.452) 0.833 (0.218-3.179) 0.273 (0.072-1.034) 0.958 (0.124-7.383)
Q3 [111 – 162) n = 26 1.778 (0.579-5.457) 9.000 (2.487-32.567)* 0.132 (0.037-0.471)* 0.273 (0.072-1.034) 0.460 (0.039-5.418)
Q4 [> 162) n = 26 0.323 (0.084-1.237) 1.474 (0.398-5.454) 0.679 (0.183-2.510) 0.273 (0.072-1.034) 0.460 (0.039-5.418)
  1. OR = odds ratio; 95% CI = odds ratio confidence interval. ORs are adjusted for age and sex; * D1 = points (< 1.5 cm], D2 = nodular dimensions [1.5 - 3 cm] & parenchymal dimensions (> 3 cm), D3 = confluent dimensions, D4 = non confluent dimensions; * p-value < 0.05 compared with the reference group Q1; ** N = number of samples = 96.